On April 22, 2026, the U.S. Department of Health and Human Services (HHS) confirmed it has blocked the publication of a Centers for Disease Control and Prevention (CDC) study demonstrating the effectiveness of COVID-19 vaccines. The research, which had already cleared internal scientific and editorial reviews, was scheduled to appear in the March 19 edition of the Morbidity and Mortality Weekly Report (MMWR). Andrew Nixon, HHS deputy assistant secretary for media relations, confirmed the decision, stating that the manuscript was rejected following an assessment that identified concerns regarding the methodological approach to estimating vaccine effectiveness.
The study utilized a "test-negative design" to evaluate vaccine performance during the 2025-2026 winter season. According to data obtained by sources familiar with the findings, the research concluded that the vaccine reduced emergency department visits by 50% and hospitalizations by 55% among healthy adults. This methodology is a long-standing standard in public health, used for decades to estimate the effectiveness of seasonal influenza and respiratory virus vaccines. Despite this, acting CDC Director Dr. Jay Bhattacharya reportedly intervened to halt the release, expressing a preference for randomized clinical trials over observational data to derive real-time estimates.
The cancellation has drawn sharp criticism from the scientific community. Dr. Michael Iademarco, who oversaw the MMWR from 2014 to 2022, described the move as unprecedented, noting that he had never seen a report blocked after reaching the final publication phase. Former CDC official Dr. Demetre Daskalakis characterized the decision as "cherry-picking" based on the biases of political leadership. Critics argue that the move undermines the CDC’s role as a source of transparent, real-time health data, particularly as the methodology in question was used in a flu vaccine study published in the MMWR just one week prior to the COVID-19 report's scheduled release.
This development follows a series of significant shifts in U.S. health policy under HHS Secretary Robert F. Kennedy Jr. In May 2025, the administration ended recommendations for COVID-19 vaccinations for pregnant women and healthy children. The decision to nix the study also coincides with a period of intense legal scrutiny for the department. On March 16, 2026, U.S. District Judge Brian E. Murphy issued a preliminary injunction blocking an HHS overhaul of the childhood immunization schedule and suspending 13 members of the recently reconstituted Advisory Committee on Immunization Practices (ACIP).
The dispute highlights a growing rift between career scientists and political appointees within federal health agencies. While HHS maintains that the rejection is a matter of ensuring the highest standards of scientific rigor, public health advocates express concern that the suppression of efficacy data could have broader implications for national health policy and public trust. The administration’s pivot toward requiring randomized trials for routine surveillance is viewed by many researchers as an impractical standard that would effectively eliminate the government's ability to provide timely updates on vaccine performance.